Table 3.
Drugs to be evaluated in the current study
| Box A: drugs to treat (complications of) liver cirrhosis19-24 | Box B: most frequently used drugs in the general population* |
|---|---|
| Metabolic syndrome | Analgesics |
| Insulins | Paracetamol |
| Oral antidiabetics Dyslipidemia | NSAIDs Opioids |
| Antilipemics | Antibiotics |
| (anti) Hepatitis B/C | Tetracyclines |
| Nucleos(t)ide analogues Interferon Direct-acting antivirals | Sulfonamides and trimethoprim Macrolides Other antibiotics |
| PBC/AIH | Gastro-intestinal drugs Antacids |
| Corticosteroids | H2-receptor antagonists |
| Ursodeoxycholic acid | Propulsives |
| Azathioprine | Stimulant laxatives |
| Mycophenolate mofetil | Bulk-forming laxatives |
| Infections | Cardiovascular drugs |
| Chinolons | Antithrombotics |
| Penicillins | Calcium antagonists |
| Esophageal varices | RAS-inhibitors |
| Proton pump inhibitors | |
| Portal hypertension | |
| Beta blocking agents | |
| Hepatorenal syndrome | |
| Terlipressin | |
| Ascites | |
| Diuretics | |
| Albumin | |
| Hepatic encephalopathy | |
| Lactitol | |
| Lactulose | |
| Rifaximin |
*Based on number of users of prescribed drugs in the Netherlands according to the GIP-database 2013 (www.gipdatabank.nl).
PBC, primary biliary cholangitis; AIH, autoimmune hepatitis